305 related articles for article (PubMed ID: 26716514)
1. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.
Cheng H; Zhang Z; Rodriguez-Barrueco R; Borczuk A; Liu H; Yu J; Silva JM; Cheng SK; Perez-Soler R; Halmos B
Oncotarget; 2016 May; 7(20):28976-88. PubMed ID: 26716514
[TBL] [Abstract][Full Text] [Related]
2. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer.
Chaudhary KR; Kinslow CJ; Cheng H; Silva JM; Yu J; Wang TJ; Hei TK; Halmos B; Cheng SK
Sci Rep; 2022 Jun; 12(1):10140. PubMed ID: 35710591
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
4. Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer.
Zhang M; Zeng J; Zhao Z; Liu Z
Mol Carcinog; 2017 Mar; 56(3):821-832. PubMed ID: 27500472
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
6. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD.
Yu M; Chen Y; Li X; Yang R; Zhang L; Huangfu L; Zheng N; Zhao X; Lv L; Hong Y; Liang H; Shan H
Cell Death Dis; 2018 May; 9(5):464. PubMed ID: 29700328
[TBL] [Abstract][Full Text] [Related]
7. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
[TBL] [Abstract][Full Text] [Related]
8. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
He W; Zhang Y; Xia S
Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Zhu J; Tao L; Jin L
Mol Med Rep; 2019 Feb; 19(2):1331-1339. PubMed ID: 30535506
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.
Xiao L; Zhou H; Li XP; Chen J; Fang C; Mao CX; Cui JJ; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2016 Jun; 7(26):40038-40046. PubMed ID: 27223073
[TBL] [Abstract][Full Text] [Related]
11. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
12. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients.
Wu C; Xu B; Yuan P; Miao X; Liu Y; Guan Y; Yu D; Xu J; Zhang T; Shen H; Wu T; Lin D
Cancer Res; 2010 Dec; 70(23):9721-9. PubMed ID: 21118971
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.
Song S; Honjo S; Jin J; Chang SS; Scott AW; Chen Q; Kalhor N; Correa AM; Hofstetter WL; Albarracin CT; Wu TT; Johnson RL; Hung MC; Ajani JA
Clin Cancer Res; 2015 Jun; 21(11):2580-90. PubMed ID: 25739674
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1.
Zhang MY; Lin J; Kui YC
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2436-2443. PubMed ID: 30964169
[TBL] [Abstract][Full Text] [Related]
17. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Hsu PC; You B; Yang YL; Zhang WQ; Wang YC; Xu Z; Dai Y; Liu S; Yang CT; Li H; Hu B; Jablons DM; You L
Oncotarget; 2016 Aug; 7(32):51922-51933. PubMed ID: 27409162
[TBL] [Abstract][Full Text] [Related]
18. MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer.
Huang C; Ma R; Yue J; Li N; Li Z; Qi D
Cell Physiol Biochem; 2015; 37(1):342-52. PubMed ID: 26316081
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis.
Zhu L; Ma G; Liu J; Deng Y; Wu Q; Chen W; Zhou Q
Medicine (Baltimore); 2019 Apr; 98(16):e15069. PubMed ID: 31008931
[TBL] [Abstract][Full Text] [Related]
20. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
